# Butterfly Network, Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Butterfly Network, Inc.](/companies/bfly.md) (CIK 1804176)
- Form: 10-Q
- Filed: 2021-11-15
- Accepted by EDGAR: Nov 15, 2021, 16:07 ET
- Period: 2021-09-30
- Accession: 0001558370-21-015970
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1804176/000155837021015970/tmb-20210930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1804176/000155837021015970/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $14.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $43.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $19.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $34.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | −$5.1m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-09-30 | $9.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $21.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $54.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$57.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$147.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 9 months, 2021-01-01 to 2021-09-30 | $645.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | −$3.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $72.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$13.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$17.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 196,095,192 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 165,656,408 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$146.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $3.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-09-30 | $153.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $543.5m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $580.3m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $45.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $129.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $451.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 55,600 characters.

*The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto for the year ended December 31, 2020 contained in Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on March 29, 2021. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021 and 2020, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.*

### Overview

We are an innovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution uses a unique combination of software and hardware enabling medical imaging to drive more clinical insight at patient point-of-care. With this technology, Butterfly created the only ultrasound transducer that can perform “whole-body imaging” in a single handheld probe using semiconductor technology. After launching our first-generation Butterfly iQ hardware product in 2019, in 2020 we launched and commercialized the second-generation product, the Butterfly iQ+. Our proprietary software and artificial intelligence (“AI”) solution are intended to make the product easy to use, integrated with the clinical workflow and accessible on a user’s smartphone or tablet, as well as healthcare enterprise systems. Our portable, usable, accessible and affordable handheld solution is protected by a robust intellectual property portfolio with more than 800 patents granted or pending.

The Butterfly iQ / iQ+ is currently cleared as a Class II medical device by the U.S. Food and Drug Administration (“FDA”), received a medical device license in Canada and has the CE mark in Europe for use by health care practitioners. It is commercially available in over 20 countries including the United States, Canada, Australia, New Zealand and throughout greater Europe.

We are focused on driving the adoption of our handheld solution in order to democratize healthcare globally. We believe that the potential global addressable ultrasound market is estimated to be $8 billion. We seek to expand the addressable market through three strategies: increasing users, expanding use cases and expanding to more care settings where the Butterfly solutions are used. We also seek to increase touchpoints with our existing and potential customers through new sales channels such as medical and nursing schools, veterinarian usage, non-governmental organizations and distributors. Generally, we currently sell directly to users through our ecommerce channel and also sell to enterprise customers through our direct sales force and distributors.

We plan to continue to invest in the development of our products and solutions across the Butterfly platform. With the launch of Butterfly iQ+, we lowered manufacturing costs and improved capabilities including lower power consumption, Needle Viz™ technology, faster frame rates and improved interoperability. Additionally, over the course of 2021, we launched multiple new software features that improve image acquisition, added features for use cases and enhanced ease of use.

While we are driving revenue growth, we are also focused on improving gross profits by working to drive operational efficiencies in our supply chain and incorporate a greater mix of higher margin products and services over time.

### COVID-19

The COVID-19 pandemic that began in 2020 has created significant global economic uncertainty. Uncertainty remains regarding the extent, timing and duration of the pandemic, including the emergence of new strains of the virus that may be more contagious or virulent and the extent to which the availability of vaccines and other safety measures will positively impact public health conditions. The uncertainty and potential economic volatility impact our customer base, supply chains, our business practices and our employees.

The COVID-19 pandemic and its economic impact have caused financial strain on our customer base due to decreased funding and other revenue shortfalls. With the recent Delta variant wave of infections, we have seen our customer base become further strained in solving immediate problems associated with the variant. As a result, some of our customers have had to shift their attention to these pressing issues, resulting in decreased sales volume.

In addition, the issues originally brought on by COVID-19 continue to have an ongoing adverse impact on global supply chains, including ours. We have experienced constraints in availability, increasing lead times and costs required to obtain some inventory components. We are actively implementing new operating efficiencies in our supply chain processes to help offset the cost increases in component parts for our device.

The pandemic caused us to make modifications to our business practices, including work from home policies, establishing strict health and safety protocols for our offices specific to COVID-19 and imposing restrictions on employee travel. Our employees have resumed traveling to perform sales-generating and corporate activities, and we have opened our offices and have allowed employees at their discretion to return to our offices. We are designing and implementing a plan to allow employees to safely resume work in the office on a more regular basis.

We continue to closely monitor the developments of COVID-19 for any material impact on our business. Given the uncertainty and potential economic volatility of the impact of the COVID-19 pandemic, the recent developments we have experienced may change based on new information that may emerge concerning COVID-19, the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.

### Business Combination

On February 12, 2021 we completed the business combination with Longview (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview Acquisition Corp. (“Longview”), Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). The Business Combination was approved by Longview's stockholders at its special meeting held on February 12, 2021. The transaction resulted in the Company being renamed to "Butterfly Network, Inc.," Legacy Butterfly being renamed “BFLY Operations, Inc.” and the Company’s Class A common stock and warrants to purchase Class A common stock commencing trading on the New York Stock Exchange ("NYSE") on February 16, 2021 under the symbol "BFLY" and “BFLY WS”, respectively. As a result of the Business Combination, we received gross proceeds of approximately $589 million.

### Recent Developments

In October 2021 we launched Butterfly iQ+ Vet, a second-generation device with sharper imaging, a new procedural guidance tool and hardware improvements that make the solution more powerful, versatile and easy-to-use for veterinarians in a variety of care settings.

### Key Performance Metrics

We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions.

### Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.

Units fulfilled increased by 1,609, or 40.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020, primarily due to increased sales from our veterinary, distributor and direct sales force revenue channels. The increased sales in these channels were offset by slowing sales in our e-commerce revenue channel.

### Subscription Mix

We define subscription mix as a percentage of our total revenue recognized in a reporting period that is subscription-based, consisting primarily of our software as a service (“SaaS”) offering. We view subscription mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors. Because the costs and associated expenses to deliver our subscription offerings are lower as a percentage of sales than the costs of sales of our products, we believe a shift towards subscription will result in an improvement in profitability and margin expansion.

Subscription mix increased by 10.9 percentage points, to 25.8% for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was due to an increased volume of units fulfilled and increases in subscription renewals, as well as the timing of revenue recognition for our SaaS and other subscription contracts and the timing of units fulfilled. Revenue from such contracts is deferred and recognized over the service period.

### Non-GAAP Financial Measures

We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

Our Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA alongside other financial performance measures prepared in accordance with U.S. GAAP, including gross profit, gross margin, operating loss and net loss.

### Adjusted Gross Profit and Adjusted Gross Margin

We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs. We calculate Adjusted Gross Margin as gross margin adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs.

Our changes in the warranty liability are excluded from gross profit and gross margin when they are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

We also exclude from gross profit and gross margin non-recurring losses on purchase commitments and non-recurring inventory write-downs when they are outside the normal course of business and in the period the expenses are incurred. The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts, and the non-recurring inventory write-down adjustments are for excess and obsolete inventory resulting from a shift in product lines.

The following table reconciles Adjusted Gross Profit to gross profit and Adjusted Gross Margin to gross margin, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

| ​ ​ ​ | ​ ​ ​ | ​ ​ Three months ended September 30, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ | ​ ​ Nine months ended September 30, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- |
| Revenue |  | $14,621 | ​ | $10,135 | ​ | $43,578 | ​ | $30,597 | ​ |
| Cost of revenue | ​ | 19,743 | ​ | 79,386 | ​ | 34,064 | ​ | 100,519 | ​ |
| **Gross profit** | **​** | **$(5,122)** | **​** | **$(69,251)** | **​** | **$9,514** | **​** | **$(69,922)** | ​ |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| **Gross margin** | **​** | **​** **(35.0)%** | **​** | **​** **(683.3)%** | **​** | **​** **21.8%** | **​** | **​** **(228.5)%** | ​ |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ |
| Add: | ​ |  | ​ |  | ​ |  | ​ |  | ​ |
| Depreciation and amortization | ​ | 131 | ​ | 23 | ​ | 291 | ​ | 69 | ​ |
| Warranty liability policy change | ​ | ​ — | ​ | ​ — | ​ | ​ (560) | ​ | ​ — | ​ |
| Loss on purchase commitments | ​ | 11,623 | ​ | 63,993 | ​ | 11,623 | ​ | 63,993 | ​ |
| Inventory write-downs | ​ | 582 | ​ | 2,570 | ​ | 582 | ​ | 2,570 | ​ |
| **Adjusted gross profit** | **​** | **$7,214** | **​** | **$(2,665)** | **​** | **$21,450** | **​** | **$(3,290)** | **​** |
| **​** | **​** | **​** **​** | **​** | **​** **​** | **​** | **​** **​** | **​** | **​** **​** | **​** |
| **Adjusted gross margin** | **​** | **​** **49.3%** | **​** | **​** **(26.3)%** | **​** | **​** **49.2%** | **​** | **​** **(10.8)%** | **​** |

### Adjusted EBITDA

We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, changes in the fair value of warrant liabilities, other expense, net, provision for income taxes, stock-based compensation, depreciation and amortization and other non-recurring items. The other non-recurring items include costs related to our executive transition, adjustments for the warranty liability policy changes, discretionary transaction bonuses, non-recurring losses on purchase commitments, non-recurring inventory write-downs and other fees incurred with the close of the Business Combination.

Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs. The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts and the non-recurring inventory write-down adjustments are for excess and obsolete inventory resulting from a shift in product lines.

The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.

*(In thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ Three months ended September 30, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ | ​ ​ Nine months ended September 30, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Net loss** |  | **$(13,561)** |  | **$(92,208)** |  | **$(17,193)** |  | **$(139,803)** | **​** |
| Interest income |  | ​ (893) |  | ​ (16) |  | ​ (1,739) |  | ​ (238) | ​ |
| Interest expense |  | ​ — |  | ​ 300 |  | ​ 645 |  | ​ 418 | ​ |
| Change in fair value of warrant liabilities | ​ | ​ (42,958) | ​ | ​ — | ​ | ​ (130,528) | ​ | ​ — | ​ |
| Other expense, net |  | ​ 428 |  | ​ 84 |  | ​ 1,320 |  | ​ 183 | ​ |
| Provision for income taxes |  | ​ (3) |  | ​ 12 |  | ​ 72 |  | ​ 32 | ​ |
| Stock based compensation |  | ​ 10,734 |  | ​ 2,382 |  | ​ 38,769 |  | ​ 7,727 | ​ |
| Depreciation and amortization |  | ​ 505 |  | ​ 311 |  | ​ 1,420 |  | ​ 904 | ​ |
| CEO transition costs | ​ | ​ — | ​ | ​ — | ​ | ​ 5,398 | ​ | ​ — | ​ |
| Warranty liability policy change | ​ | ​ — | ​ | ​ — | ​ | ​ (560) | ​ | ​ — | ​ |
| Transaction bonus | ​ | ​ — | ​ | ​ — | ​ | ​ 1,653 | ​ | ​ — | ​ |
| Loss on purchase commitments |  | ​ 11,623 |  | ​ 63,993 |  | ​ 11,623 |  | ​ 63,993 | ​ |
| Inventory write-downs |  | ​ 582 |  | ​ 2,570 |  | ​ 582 |  | ​ 2,570 | ​ |
| **Adjusted EBITDA** |  | **$(33,543)** |  | **$(22,572)** |  | **$(88,538)** |  | **$(64,214)** | **​** |

### Description of Certain Components of Financial Data

### Revenue

Revenue consists of revenue from the sale of products, such as medical devices and accessories, and related services, classified as subscription revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and Support. SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products, which include the ultrasound devices and any ultrasound device accessories, revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.

Over time as adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward subscriptions. The quarterly revenue mix may be impacted by the timing of device sales.

From time to time, we may transition to higher prices for our product and services. The transition to higher prices may impact the timing and volume of sales and the related revenue. Partially as a result of a pricing adjustment in August 2021, we are seeing slowing sales in our ecommerce revenue channel.

### Cost of revenue

Loss on product purchase commitments relates to inventory supply agreements where the expected losses exceed the benefit of the contracts. The Company considers a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points include Company-specific forecasts which are reliant on the Company’s limited sales history, agreement-specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates. Future events may differ from those assumed in the Company’s assessment, and therefore the loss may change in the future.

Cost of product revenue consists of product costs including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and decrease as a percentage of revenues over time as we focus on operational efficiencies in our supply chain. Our vendors may from time to time increase prices of certain inventory components that could in the future offset the operational efficiencies in our supply chain.

Cost of subscription revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate an improvement in profitability and margin expansion over time as our mix shifts increasingly towards subscriptions. We plan to continue to invest additional resources into our products to expand and further develop our offerings. The level and timing of investment in these areas could affect our cost of revenue in the future. We expect the cost of revenue to increase as a percentage of revenue in the near term due to the investments we are making, which will generally increase more rapidly than that of subscription revenue.

### Research and development (R&D)

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services and improving existing products and services, which we define as not having reached the point of commercialization, and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities. Prospectively, we expect R&D spending to increase in absolute dollars in the near term and then fluctuate over time due to the level and timing of our product development efforts. R&D as a percentage of revenue will fluctuate given the level and timing of the product development efforts as well the amount of revenue recognized in a period.

### Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, digital marketing, advertising, promotional, as well as conferences, meetings and other events and related facilities and information technology costs. We expect our sales and marketing expenses to increase in absolute dollars in the long term as we continue to increase the size of our direct sales force and sales support personnel and expand into new products and markets. We expect our sales and marketing expenses will also increase in the near term as we promote our brand through marketing and advertising initiatives, expand market presence and hire additional personnel to drive penetration and generate leads. We expect that sales and marketing expenses as a percentage of revenues will increase in the near term and then fluctuate over time as we evaluate expansion opportunities.

### General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, patent and filing fees, facilities costs and outside services. Outside services consist of professional services, legal and other professional fees. We expect our general and administrative expenses to increase in absolute dollars in the foreseeable future. We anticipate general and administrative expenses as a percentage of revenues will fluctuate over time due to the timing and amount of these expenses.

### Results of Operations

We operate as a single reportable segment to reflect the way our chief operating decision maker (“CODM”) reviews and assesses the performance of the business. The accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

*(in thousands)*

| ​ ​ ​ ​ Revenue: | ​ ​ ​ ​ ​ | ​ ​ Three months ended September 30, 2021 ​ ​ Dollars | ​ ​ ​ | ​ ​ ​ % of ​ revenue ​ | ​ ​ ​ ​ | ​ ​ 2020 ​ ​ Dollars | ​ ​ ​ | ​ ​ % of revenue | ​ ​ ​ ​ ​ | ​ ​ Nine months ended September 30, 2021 ​ ​ Dollars | ​ ​ ​ | ​ ​ ​ % of ​ revenue ​ | ​ ​ ​ ​ | ​ ​ 2020 ​ ​ Dollars | ​ ​ ​ | ​ ​ % of revenue |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: |
| Product | ​ | $10,848 |  | 74.2% | ​ | $8,621 |  | 85.1% | ​ | $33,455 |  | 76.8% | ​ | $25,820 |  | 84.4% |
| Subscription | ​ | ​ 3,773 |  | 25.8% | ​ | ​ 1,514 |  | 14.9% | ​ | ​ 10,123 |  | 23.2% | ​ | ​ 4,777 |  | 15.6% |
| **Total revenue:** | ​ | $14,621 |  | 100.0% | ​ | $10,135 |  | 100.0% | ​ | $43,578 |  | 100.0% | ​ | $30,597 |  | 100.0% |
| Cost of revenue: | ​ | ​ |  |  | ​ | ​ |  | ​ | ​ | ​ |  |  | ​ | ​ |  | ​ |
| Loss on product purchase commitments | ​ | ​ 11,623 | ​ | 79.5% | ​ | ​ 63,993 | ​ | 631.4% | ​ | ​ 11,623 | ​ | 26.7% | ​ | ​ 63,993 | ​ | 209.1% |
| Product | ​ | ​ 7,584 |  | 51.9% | ​ | ​ 14,619 |  | 144.2% | ​ | ​ 21,090 |  | 48.4% | ​ | ​ 35,266 |  | 115.3% |
| Subscription | ​ | ​ 536 |  | 3.7% | ​ | ​ 774 |  | 7.6% | ​ | ​ 1,351 |  | 3.1% | ​ | ​ 1,260 |  | 4.1% |
| **Total cost of revenue:** | ​ | $19,743 |  | 135.0% | ​ | $79,386 |  | 783.3% | ​ | $34,064 |  | 78.2% | ​ | $100,519 |  | 328.5% |
| **Gross profit** | **​** | **$(5,122)** |  | (35.0)% | ​ | **$(69,251)** |  | (683.3)% | **​** | **$9,514** |  | 21.8% | ​ | **$(69,922)** |  | (228.5)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Operating expenses: | ​ | ​ |  |  | ​ | ​ |  | ​ | ​ | ​ |  |  | ​ | ​ |  | ​ |
| Research and development | ​ | ​ 21,654 |  | 148.1% | ​ | ​ 11,971 |  | 118.1% | ​ | ​ 54,459 |  | 125.0% | ​ | ​ 36,427 |  | 119.1% |
| Sales and marketing | ​ | ​ 14,203 |  | 97.1% | ​ | ​ 5,538 |  | 54.6% | ​ | ​ 34,550 |  | 79.3% | ​ | ​ 17,408 |  | 56.9% |
| General and administrative | ​ | ​ 16,008 |  | 109.5% | ​ | ​ 5,068 |  | 50.0% | ​ | ​ 67,928 |  | 155.9% | ​ | ​ 15,651 |  | 51.2% |
| **Total operating expenses** | **​** | **$51,865** |  | 354.7% | ​ | **$22,577** |  | 222.8% | **​** | **$156,937** |  | 360.1% | ​ | **$69,486** |  | 227.1% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Loss from operations** | **​** | **$(56,987)** |  | (389.8)% | **​** | **$(91,828)** |  | (906.0)% | **​** | **$(147,423)** |  | (338.3)% | **​** | **$(139,408)** |  | (455.6)% |
| Interest income | ​ | ​ 893 |  | 6.1% | ​ | ​ 16 |  | 0.2% | ​ | ​ 1,739 |  | 4.0% | ​ | ​ 238 |  | 0.8% |
| Interest expense | ​ | ​ — |  | —% | ​ | ​ (300) |  | (3.0)% | ​ | ​ (645) |  | (1.5)% | ​ | ​ (418) |  | (1.4)% |
| Change in fair value of warrant liabilities | ​ | ​ 42,958 | ​ | 293.8% | ​ | ​ — | ​ | —% | ​ | ​ 130,528 | ​ | 299.5% | ​ | ​ — | ​ | —% |
| Other income (expense), net | ​ | ​ (428) |  | (2.9)% | ​ | ​ (84) |  | (0.8)% | ​ | ​ (1,320) |  | (3.0)% | ​ | ​ (183) |  | (0.6)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Loss before provision for income taxes** | **​** | **$(13,564)** |  | (92.8)% | ​ | **$(92,196)** |  | (909.7)% | **​** | **$(17,121)** |  | (39.3)% | ​ | **$(139,771)** |  | (456.8)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Provision for income taxes | ​ | ​ (3) |  | (0.0)% | ​ | ​ 12 |  | 0.1% | ​ | ​ 72 |  | 0.2% | ​ | ​ 32 |  | 0.1% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Net loss** | **​** | **$(13,561)** |  | (92.8)% | ​ | **$(92,208)** |  | (909.8)% | **​** | **$(17,193)** |  | (39.5)% | ​ | **$(139,803)** |  | (456.9)% |

### Comparison of the three months ended September 30, 2021 and 2020

### Revenue

*(in thousands)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Three months ended September 30, 2021 ​ | ​ ​ | ​ ​ 2020 ​ | ​ ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Product |  | $10,848 | ​ | $8,621 | ​ | $2,227 | 25.8% |
| Subscription |  | ​ 3,773 | ​ | ​ 1,514 | ​ | ​ 2,259 | 149.2% |
| Total revenue: | ​ | $14,621 | ​ | $10,135 | ​ | $4,486 | 44.3% |

Total revenue increased by $4.5 million, or 44.3%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020.

Product revenue increased by $2.2 million, or 25.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts domestically and internationally.

Subscription revenue increased by $2.3 million, or 149.2%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.

### Cost of revenue

*(in thousands)*

| ​ ​ Cost of revenue: | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ ​ | ​ ​ ​ ​ 2020 ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | ---: | ---: | ---: |
| Loss on product purchase commitments | ​ | $11,623 ​ | $63,993 ​ | $(52,370) | (81.8)% |
| Product |  | ​ 7,584 ​ | ​ 14,619 ​ | ​ (7,035) | (48.1)% |
| Subscription |  | ​ 536 ​ | ​ 774 ​ | ​ (238) | (30.7)% |
| Total cost of revenue | ​ | $19,743 ​ | $79,386 ​ | $(59,643) | (75.1)% |
| Percentage of revenue | ​ | 135.0% | 783.3% |  | ​ |

Loss on product purchase commitments decreased by $52.4 million, or 81.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The overall decrease is primarily due to a decrease in the purchase commitment loss related to a certain third-party vendor of $44.8 million. The decreased loss related to such vendor is due to the purchase commitment loss taken in the prior fiscal year as an estimate of future excess inventory and the additional purchase commitment loss recorded for the three months ended September 30, 2021. The additional loss was the result of changes to certain factors management considers when determining the existence and scope of a loss for the minimum purchase commitment. Additionally, the overall decrease is due to the non-recurrence of losses on other purchase commitments with other third-party vendors recorded in the prior year of $7.6 million.

Cost of product revenue decreased by $7.0 million, or 48.1%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, which is less costly to produce, in the quarter ended September 30, 2021 as opposed to the Butterfly IQ in the quarter ended September 30, 2020. The overall decrease of product cost of revenue was primarily driven by decreases in product costs of $2.0 million and a decrease in net realizable value inventory adjustments and excess and obsolete inventory charges of $5.7 million. The decreases were partially offset by increases in component product costs related to global supply chain constraints of $0.5 million and other items that were not significant.

Cost of subscription revenue decreased by $0.2 million, or 30.7%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was primarily driven by decreased payment processing fees partially offset by increased cloud hosting costs.

### Research and development

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development |  | $21,654 | $11,971 | $9,683 | 80.9% |
| Percentage of revenue | ​ | 148.1% | 118.1% |  | ​ |

Research and development expenses increased by $9.7 million, or 80.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation expense of $7.9 million and an increase in professional service fees of $1.1 million as we continue to invest in expanding our overall product development capabilities and resources.

### Sales and marketing

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Sales and marketing |  | $14,203 | $5,538 | $8,665 | 156.5% |
| Percentage of revenue | ​ | 97.1% | 54.6% |  | ​ |

33

Sales and marketing expenses increased by $8.7 million, or 156.5%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation of $5.5 million, an increase in demand generation costs of $1.3 million due to investments made to promote sales growth and an increase in travel, an increase in overhead costs of $0.6 million and entertainment costs of $0.7 million primarily related to the Company’s annual sales conference.

### General and administrative

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| General and administrative |  | $16,008 | $5,068 | $10,940 | 215.9% |
| Percentage of revenue | ​ | 109.5% | 50.0% |  | ​ |

General and administrative expenses increased by $10.9 million, or 215.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel cost including stock-based compensation and benefits of $7.8 million associated with investments to scale up our back-office support and executive functions. In addition, the increase in general and administrative expenses is due to increased recruiting expense of $0.5 million to support our investments in personnel growth, increased professional service fees of $1.3 million and other general and administrative costs incremental to being a publicly traded company of $0.8 million.

### Loss from operations

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Loss from operations |  | $(56,987) | $(91,828) | $34,841 | (37.9)% |
| Percentage of revenue | ​ | (389.8)% | (906.0)% |  | ​ |

Loss from operations decreased by $34.8 million, or 37.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was primarily a result of an increase in gross profit of $64.1 million partially offset by increases in operating expenses of $29.3 million. The increase in gross profit was due to higher volume of sales, lower cost of product revenue and lower losses on product purchase commitments.

### Net loss

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Net loss |  | $(13,561) | $(92,208) | $78,647 | (85.3)% |
| Percentage of revenue | ​ | (92.8)% | (909.8)% |  | ​ |

Net loss decreased by $78.6 million, or 85.3%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease in the net loss was primarily a result of a decrease in the operating loss of $34.8 million and the gain for the change in the fair value of the warrant liabilities of $43.0 million. The warrant liabilities were recorded as part of the Business Combination and therefore did not exist in the prior year.

### Comparison of the nine months ended September 30, 2021 and 2020

### Revenue

*(in thousands)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ | ​ ​ 2020 ​ | ​ ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Product |  | $33,455 | ​ | $25,820 | ​ | $7,635 | 29.6% |
| Subscription |  | ​ 10,123 | ​ | ​ 4,777 | ​ | ​ 5,346 | 111.9% |
| Total revenue: | ​ | $43,578 | ​ | $30,597 | ​ | $12,981 | 42.4% |

34

Total revenue increased by $13.0 million, or 42.4%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020.

Product revenue increased by $7.6 million, or 29.6%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts domestically and internationally. For the nine months ended September 30, 2020, revenue was positively impacted by COVID-19, as the Butterfly iQ was utilized in the monitoring of acute symptoms of COVID-19. We are unable to measure precisely the positive impact of COVID-19 on our revenue for the nine months ended September 30, 2020.

Subscription revenue increased by $5.3 million, or 111.9%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.

### Cost of revenue

*(in thousands)*

| ​ ​ Cost of revenue: | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ ​ | ​ ​ ​ ​ 2020 ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ | ​ ​ ​ % Change ​ |
| --- | --- | ---: | ---: | ---: | --- | ---: |
| Loss on product purchase commitments | ​ | $11,623 ​ | $63,993 ​ | $(52,370) | ​ | (81.8)% |
| Product |  | ​ 21,090 ​ | ​ 35,266 ​ | ​ (14,176) |  | (40.2)% |
| Subscription |  | ​ 1,351 ​ | ​ 1,260 ​ | ​ 91 |  | 7.2% |
| Total cost of revenue | ​ | $34,064 ​ | $100,519 ​ | $(66,455) |  | (66.1)% |
| Percentage of revenue | ​ | 78.2% | 328.5% |  |  | ​ |

Loss on product purchase commitments decreased by $52.4 million, or 81.8%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The overall decrease is primarily due to a decrease in the purchase commitment loss related to a certain third-party vendor of $44.8 million. The decreased loss related to such vendor is due to the purchase commitment loss taken in the prior fiscal year as an estimate of future excess inventory and the additional purchase commitment loss recorded for the nine months ended September 30, 2021. The additional loss was the result of changes to certain factors management considers when determining the existence and scope of a loss for the minimum purchase commitment. Additionally, the overall decrease is due to the non-recurrence of losses on other purchase commitments with other third-party vendors recorded in the prior year of $7.6 million.

Cost of product revenue decreased by $14.2 million, or 40.2%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, which is less costly to produce in the period ended September 30, 2021 as opposed to the Butterfly IQ in the period ended September 30, 2020. The overall decrease of product cost of revenue was primarily driven by decreases in product costs of $6.9 million, a decrease in warranty expense of $1.6 million and a decrease in net realizable value inventory adjustments and excess and obsolete inventory charges of $7.6 million. The decreases were partially offset by an increase in component product costs related to global supply chain constraints of $0.6 million, an increase in royalty fees due to increased sales of the Butterfly IQ+ of $0.6 million and an increase in payment processing fees of $0.6 million.

Cost of subscription revenue increased by $0.1 million, or 7.2%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by increased cloud hosting costs and amortization expense partially offset by decreased payment processing fees.

### Research and development

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development |  | $54,459 | $36,427 | $18,032 | 49.5% |
| Percentage of revenue | ​ | 125.0% | 119.1% |  | ​ |

35

Research and development expenses increased by $18.0 million, or 49.5%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation expense of $16.3 million and an increase in professional service fees of $1.5 million as we continue to invest in expanding our overall product development capabilities and resources.

### Sales and marketing

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Sales and marketing |  | $34,550 | $17,408 | $17,142 | 98.5% |
| Percentage of revenue | ​ | 79.3% | 56.9% |  | ​ |

Sales and marketing expenses increased by $17.1 million, or 98.5%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by an increase in personnel cost including stock-based compensation of $11.5 million, an increase in demand generation costs of $3.1 million due to investments made to promote sales growth, an increase in travel and entertainment costs of $0.7 million related to internal and external events and an increase in professional service fees of $0.8 million to support our sales and marketing efforts.

### General and administrative

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| General and administrative |  | $67,928 | $15,651 | $52,277 | 334.0% |
| Percentage of revenue | ​ | 155.9% | 51.2% |  | ​ |

General and administrative expenses increased by $52.3 million, or 334.0%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase is primarily due to an increase in stock-based compensation expense of $23.2 million due to the additional awards granted and the performance condition for certain restricted stock units being achieved upon the Closing of the Business Combination. In addition to stock-based compensation, the increase was primarily driven by increased personnel costs of $13.7 million due to investments made to scale up our back-office support and executive functions, certain costs with regards to our CEO transition, an increase in recruiting expense of $3.5 million, an increase in professional services of $7.7 million and an increase in other general and administrative costs incremental to being a publicly traded company of $2.4 million.

### Loss from operations

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Loss from operations |  | $(147,423) | $(139,408) | $(8,015) | 5.7% |
| Percentage of revenue | ​ | (338.3)% | (455.6)% |  | ​ |

Loss from operations increased by $8.0 million, or 5.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily a result of increases in operating expenses of $87.5 million partially offset by an increase in gross profit of $79.4 million. The increase in gross profit was primarily due to a higher volume of sales, lower cost of product revenue and lower losses on purchase commitments.

### Net loss

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Nine months ended September 30, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Net loss |  | $(17,193) | $(139,803) | $122,610 | (87.7)% |
| Percentage of revenue | ​ | (39.5)% | (456.9)% |  | ​ |

Net loss decreased by $122.6 million, or 87.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This decrease in net loss was primarily a result of the gain for the change in the fair value of the warrant liabilities of $130.5 million. The warrant liabilities were recorded as part of the Business Combination and therefore did not exist in the prior year. The gain was partially offset by the increased loss from operations of $8.0 million.

### Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations and issuances of preferred stock and convertible notes. In addition, on February 12, 2021, we completed the Business Combination, and as a result we received gross proceeds of approximately $589 million. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have been historically negative as we continue to develop new products and services and increase our sales and marketing efforts. We expect to be cash flow negative on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect to continue to incur losses from operations, as we continue to invest in research and development of our products and in sales and marketing efforts into expanding new markets and verticals.

We expect that the funds raised in connection with the Business Combination and cash flows from operations will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use the funds raised in connection with the Business Combination to scale our sales and marketing capabilities, develop new products and services and for working capital and general corporate purposes.

Our cash and cash equivalents and investments in marketable securities balance as of September 30, 2021 was $469.4 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.

The Company has restricted cash of $4.0 million as of September 30, 2021 to secure a letter of credit for one of the Company’s leases. The Company expects to maintain the letter of credit as security deposit for the duration of the lease.

### Cash flows

### Comparison of the period for the nine months ended September 30, 2021 and September 30, 2020

The following table summarizes our sources and uses of cash for the nine months ended September 30, 2021 and September 30, 2020:

*(in thousands)*

| ​ ​ ​ ​ ​ | ​ ​ Nine months ended September 30, 2021 | ​ ​ ​ ​ 2020 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(146,410) | $(61,077) |
| Net cash used in investing activities | ​ (319,769) | ​ (2,597) |
| Net cash provided by financing activities | ​ 563,299 | ​ 25,358 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $97,120 | $(38,316) |

### Net cash used in operating activities

Net cash used in operating activities represents the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by historical financing activities such as the Business Combination will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.

Net cash used in operating activities increased by $85.3 million, or 139.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase in net cash used in operating activities was due to a $86.4 million increase in accrued purchase commitments resulting from increased purchases of inventory components and purchase commitment losses recorded during the period. This increase was partially offset by a decrease of $13.9 million in inventories due to the costs of revenue recognized during the period. The increase in net cash used in operating activities was also due to an $8.6 million increase in prepaid expenses and other assets and a $10.6 million increase of vendor advances to be used in operations, as well as a $11.6 million increase in accounts payable and accrued expenses due to the timing of expenses and payments. Additionally, there was a $105.4 million increase in adjustments to reconcile net loss partially offset by a $122.6 million decrease in net losses.

### Net cash used in investing activities

Net cash used in investing activities increased by $317.2 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to the investment activity for the funds received from the Business Combination.

### Net cash provided by financing activities

For the nine months ended September 30, 2021, net cash provided by financing activities increased by $537.9 million compared to the nine months ended September 30, 2020. The increase was primarily due to net proceeds from the Business Combination of $547.8 million. Additionally, the proceeds from the exercise of stock options increased by $18.9 million which was partially offset by a $4.4 million loan repayment under the Paycheck Protection Program, the non-recurrence of $20.7 million of proceeds from the issuance of convertible debt in fiscal 2020 and $4.3 million of proceeds from the loan payable issued in fiscal 2020.

### Contractual Obligations

As of September 30, 2021, our contractual obligations were as follows:

*(in thousands)*

| ​ | ​ | ​ ​ Total | ​ | ​ ​ \< 1 year | ​ | ​ ​ 1-3 Years | ​ | ​ ​ 3-5 Years | ​ | ​ ​ \> 5 years |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Operating leases | ​ | $42,864 | ​ | $1,828 | ​ | $8,139 | ​ | $9,400 | ​ | $23,497 |
| Purchase obligations (1) | ​ | ​ 129,467 | ​ | ​ 59,576 | ​ | ​ 69,891 | ​ | ​ — | ​ | ​ — |
| Total contractual obligations | ​ | $172,331 | ​ | $61,404 | ​ | $78,030 | ​ | $9,400 | ​ | $23,497 |

(1) Purchase obligations include all legally binding contracts and relate to firm commitments for inventory purchases. Our purchase obligations are related to a contract for a key inventory component in our manufacturing process. Purchase orders that are not binding agreements are excluded from the table above.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K.

### Recently Adopted Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 “Summary of Significant Accounting Policies – Recent Accounting Pronouncements Adopted” to our condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

### Emerging Growth Company

We are an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by the FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained in this report may be different than the information you receive from other public companies.

We also intend to take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding non-binding advisory votes on executive compensation and golden parachute payments.

However, based on the market value of the Company's common stock held by non-affiliates as of June 30, 2021, the Company expects to become a large-accelerated filer and thus cease to be an emerging growth company on December 31, 2021. At that time, the Company will be required to adopt new or revised accounting standards as required by public companies, including those standards which the Company had previously deferred pursuant to the JOBS Act. Additionally, the Company will no longer be able to take advantage of the reduced regulatory and reporting requirements of emerging growth companies described above.

## Market risk

As filed, 962 characters.

### Interest Rate Risk

We did not have any floating rate debt as of September 30, 2021. Our cash, cash equivalents and marketable securities are comprised primarily of bank deposits, money market accounts and equity interests in mutual funds. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

### Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

## Controls and procedures

As filed, 5,822 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that, solely due to the Company’s material weakness as described below and in Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020 filed on May 12, 2021, our disclosure controls and procedures were not effective as of September 30, 2021.

### Material Weakness in Internal Control over Financial Reporting

As previously disclosed in our Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020, we identified a material weakness in our internal controls over financial reporting related to inaccurate accounting for public warrants and private placement warrants issued in connection with our initial public offering. Notwithstanding this material weakness, management has concluded that our unaudited financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

### Plan for Remediation of the Material Weakness in Internal Control over Financial Reporting

In response to this material weakness, the Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we are improving these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards.

We are continually working to remediate the identified material weakness in internal control over financial reporting and execute on our plan to remediate the material weakness. Our plans at this time include acquiring enhanced access to accounting literature, research materials and documents and improving the communication among our personnel and third-party professionals with whom we may consult regarding the application of complex accounting transactions.

Our remediation plan can only be accomplished over time and will be continually reviewed to determine that it is achieving its objectives. We believe we are making progress toward achieving the effectiveness of our internal controls and disclosure controls; however we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

### Changes in Internal Control over Financial Reporting

Other than the changes made to remediate the material weakness described above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

## Risk factors

As filed, 435 characters.

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on March 29, 2021, as amended on May 12, 2021 (the “2020 Annual Report on Form 10-K”). There have been no material changes to the risk factors described in the 2020 Annual Report on Form 10-K.

Filed Nov 15, 2021.
Source: SEC EDGAR, the filing index for accession 0001558370-21-015970. Last ingested by Listed: Nov 14, 2026, 23:40 ET. No prices; not investment advice.
